# BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy

> **NCT01873404** · PHASE2 · COMPLETED · sponsor: **Biogen** · enrollment: 183 (actual)

## Conditions studied

- Painful Lumbar Radiculopathy
- Sciatica
- Radiculopathy

## Interventions

- **DRUG:** BG00010
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01873404
- **Lead sponsor:** Biogen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-06
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 183 (ACTUAL)
- **Last updated:** 2015-09-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01873404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01873404, "BG00010 (Neublastin) Phase 2 Multiple Dose Adaptive Design in Participants With Painful Lumbar Radiculopathy". Retrieved via AI Analytics 2026-06-07 from https://api.ai-analytics.org/clinical/NCT01873404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*